<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"><html xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>1746-6148-2-35.fm</title>
<meta name="Author" content="inal.ramadan"/>
<meta name="Creator" content="FrameMaker 7.0"/>
<meta name="Producer" content="Acrobat Distiller 7.0 (Windows)"/>
<meta name="CreationDate" content=""/>
</head>
<body>
<pre>
BMC Veterinary Research

BioMed Central

Open Access

Research article

The molecular epidemiology of Foot-and-Mouth Disease virus
serotypes A and O from 1998 to 2004 in Turkey
Joern Klein1, Ãœnal Parlak2, Fuat Ã–zyÃ¶rÃ¼k2 and Laurids S Christensen*1
Address: 1Danish Institute for Food and Veterinary Research, Department of Virology, Lindholm, 4771 Kalvehave, Denmark and 2Foot-and-Mouth
Disease Institute, Ankara, Turkey
Email: Joern Klein - jkle@dfvf.dk; Ãœnal Parlak - unalp@fmd.gov.tr; Fuat Ã–zyÃ¶rÃ¼k - fuato@fmd.gov.tr; Laurids S Christensen* - lsi@dfvf.dk
* Corresponding author

Published: 04 December 2006
BMC Veterinary Research 2006, 2:35

doi:10.1186/1746-6148-2-35

Received: 07 July 2006
Accepted: 04 December 2006

This article is available from: http://www.biomedcentral.com/1746-6148/2/35
Â© 2006 Klein et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract
Background: Foot-and-Mouth Disease (FMD) causes significant economic losses in Turkish livestock.
We have analysed the genetic diversity of the 1D sequences, encoding the hypervariable surface protein VP1, of Turkish
isolates of serotype A and O collected from 1998 to 2004 in order to obtain epidemiological and immunological
information.
Results: The 1D coding region of 33 serotype O and 20 serotype A isolates, obtained from outbreaks of FMD between
1998 and 2004, was sequenced.
For serotype A, we confirmed the occurrence of the two subtypes IRN99 and IRN96. These subtypes are most divergent
within the region encoding the immuno-dominant GH-loop. Also a close relationship to Foot-and-Mouth Disease virus
(FMDV) serotype A isolates obtained from outbreaks in Iraq and Iran were detected and a clustering of isolates collected
during the same period of time were found.
The analysis of the deduced amino-acid sequences of these subtypes revealed evidence of positive selection in one site
and one deletion, both within the GH-loop region. By inferring the ancestral history of the positively selected codon,
two potential precursors were found. Furthermore, the structural alignment of IRN99 and IRN96 revealed differences
between the tertiary structures of these subtypes.
The similarity plot of the serotype O isolates suggested a more homogeneous group than the serotype A isolates.
However, phylogenetic analysis revealed two major groups, each further divided in subgroups, of which some only
consisted of Turkish isolates.
Positively selected sites and structural differences of the Turkish isolates analysed, were not found.
Conclusion: The sequence and structural analysis of the IRN99 strains is indicative of positive selection suggesting an
immunological advantage compared to IRN96. However, results of antigenic comparison reported elsewhere do not
substantiate such a conclusion. There is evidence that IRN99 was introduced to Turkey, in all probability from Iran.
Since, a member of the IRN96 lineage was included as a component of the FMDV vaccine produced since 2000, the
outbreaks caused by IRN96 strains in 2004 could be due to incomplete vaccine coverage.
The Turkish type O strains, all with a VP1 structure similar to the O1/Manisa/69 vaccine, appear in several sublineages.
Whether these sublineages reflect multiple samplings from a limited number of outbreaks, or if they reflect crossboundary introductions is not clear.

Page 1 of 13
(page number not for citation purposes)

BMC Veterinary Research 2006, 2:35

Background
Foot-and-Mouth Disease (FMD) is an acute, highly communicable and economically important disease caused by
Foot-and-Mouth Disease virus (FMDV). Animals that can
be affected include cattle, swine, sheep, goats, wild pigs,
wild ruminants and buffaloes [1]. FMDV is a positive
sense single-stranded RNA virus (genus Aphthovirus, family Picornaviridae) occurring in seven serotypes, O, A, Asia
1, C, SAT 1, SAT 2 and SAT 3, each with a wide spectrum
of antigenic and epidemiological different subtypes. The
wide diversity is considered a consequence of the high
mutation rate and quasi-species dynamic [2].
FMD has been one of the most important diseases causing
significant economic losses in the Turkish livestock sector.
Together with production losses, export restrictions on
several agricultural products cause additional losses to the
Turkish economy [3].
Turkey is of special interest for the European countries,
because it is the natural connection to Asia, where FMD is
enzootic and thus serves as buffer zone against FMD [3].
The two prevalent serotypes in Turkey are A and O [4], and
especially the pandemic FMDV serotype O is a major
threat to Europe, because it is the most aggressive serotype
[5]. However, this type O is still covered by the O1/Manisa/69 vaccine [4].
Serotype A displays a great antigenic diversity of subtypes
and there is also often no cross-protection between them
[5]. Since 1999 two subtypes of serotype A have been circulating in Turkey, designated by the World reference Laboratory IAH Pirbright as IRN96 and IRN99 [6].
Turkey practices vaccination against FMD, using a self produced trivalent vaccine consisting of O1/Manisa/69, Asia1
and since September 2000 a member of the IRN96 lineage
as a replacement for A22, previously included [personal
communication].
Due to the introduction of a twice-yearly national vaccination campaign in 1996, the number of FMD outbreaks has
decreased significantly, but not homogeneously over the
whole country, which may be explained by vaccine failure
or incomplete vaccine coverage [7].
A common and major epitope of FMDV is located within
the surface protein VP1, containing the immuno-dominant GH-loop and the RGD-integrin binding motif, essential for cell attachment [8]. Changes in this protein may
cause vaccine failure and changes in host specificity [9].
We describe the genetic diversity of the 1D nucleotide
sequence which encodes for the VP1 protein, in isolates

http://www.biomedcentral.com/1746-6148/2/35

obtained from outbreaks in Turkish cattle herds between
1998 and 2004 and analyse the data with regard to potential epidemiological information and to establish possibly
whether FMD outbreaks are caused by viruses persistently
circulating and evolving in Turkey or by strains introduced to Turkey.

Results
Phylogenetic inference
The 1D nucleotide sequence similarity scan (Figure 1) of
the Turkish isolates of the present study reveals two well
separated groups for serotype A. The two groups are most
similar at position 90 nt with 8% divergence given a windows size of 20 nt and most divergent at position 490
with 31% divergence. The latter region encodes the
immuno-dominant GH-loop. The diversity within each of
the two serotype A groups is low within a range of 2â€“4%.

Serotype O, with O1/Manisa/69 as reference sequence,
displays one homogeneous group, with a diversity in the
range 9%.
The Bayesian tree, based on the 1D nucleotide sequence of
serotype A isolates shown in Figure 2 reveals three clusters
in Turkey, related to A22, IRN96 and IRN99. The most
recent isolate of the A22 cluster, for which sequence information is available was collected in Iraq in 1995. The A22
cluster is distinctly separated from the IRN99 and IRN96
lineages as supported by a clade credibility value of 1.0
and the IRN96 and IRN99 clusters are separated as supported by a clade credibility value of 0.97.
The IRN96 cluster is further subdivided into two temporal
divergent groups, I and II. The isolates of group I all originate from outbreaks in 1998, it was two years before this
lineage was included in the Turkish FMD vaccine.
The IRN99 related viruses display a single, not further subdivided, phylogenetic structure; with the oldest isolate
DQ296550 Igdir/06.99, obtained from an outbreak in
June 1999 in the province Igdir, close to the Iranian border. Another member of IRN99 lineage is the isolate A/
IRN/22/99# (sequence information kindly provided from
IAH Pirbright) obtained from an outbreak in Iran in 1999.
The inferred phylogeny of serotype O isolates (Figure 3),
with the vaccine lineage as outgroup, displayed two major
clusters A and B, supported by a clade credibility value of
1.0 (Figure 3).
Cluster A is split into the two groups I and II. Group I consists of sequences derived from FMD outbreaks in Pakistan and Iran in addition to a single outbreak in January/
February 2004 in the Mersin region of Turkey. The differential success, expressed as correlation to the number of

Page 2 of 13
(page number not for citation purposes)

BMC Veterinary Research 2006, 2:35

http://www.biomedcentral.com/1746-6148/2/35

Similarity plot of the 1D nucleotide sequence from the Turkish serotypes O (upper panel) and A (lower panel) obtained in this
Figure
study 1
Similarity plot of the 1D nucleotide sequence from the Turkish serotypes O (upper panel) and A (lower panel)
obtained in this study. Each coloured line indicates a single FMDV nucleotide sequence.

Page 3 of 13
(page number not for citation purposes)

BMC Veterinary Research 2006, 2:35

http://www.biomedcentral.com/1746-6148/2/35

AY593803 Brazil 1979
AY593802 Uruguay
NC011450 Holland 1942
1.00

AY593776 Germany 1981
0.54

AY593792 Italy 1962
1.00

AY593778 Spain 1962
AY593789 Argentina 1961
AY593772 Turkey 1972

0.99
1.00

A22

AY593765 Turkey 1965
1.00

AY593764 Iraq 1992
0.96

AY593762 Iraq 1995
0.75

DQ296535 Ankara/02.98
0.27

DQ296534 Burdur/03.98
0.43

DQ296536 Burdur/03.98
0.40

DQ296542 Kutahya/01.98
0.98

0.71

I

DQ296543 Aydin/03.98

1.00

AY593791 Iran 1998

IRN96

0.32

DQ296538 Aydin/01.98
0.78

DQ296537 Balikesir/01.98

1.00

A/IRN/9/2003#
0.60

DQ296552 Afyon/05.04

0.81

DQ296532 Burdur/06.04
1.00

0.82
0.97

DQ296533 Burdur/06.04

II

A/IRQ/24/2002#
0.96

A/IRQ/100/2002#
0.35

A/IRQ/59/2002#
DQ296550 Igdir/06.99
1.00

*

A/IRN/22/99#
DQ296544 Kayseri/11.00

0.46

DQ296539 Afyon/06.03
1.00

1.00

A/TUR/5/2003#

0.73

DQ296540 Afyon/06.03
0.95
1.00

0.1

DQ296541 Afyon/06.03

IRN99

DQ296545 Erzurum/06.03
0.61

DQ296548 Afyon/06.03
0.34

DQ296549 Elazig/11.03
1.00

DQ296546 Kirsehir/05.04
1.00

DQ296547 Sakarya/03.04

Bayesian2phylogenetic analysis of the 1D (VP1) nucleotide sequence of Turkish serotype A isolates (black) and related pubFigure
lished sequences (grey)
Bayesian phylogenetic analysis of the 1D (VP1) nucleotide sequence of Turkish serotype A isolates (black) and
related published sequences (grey). Numbers on the nodes indicate clade credibility values. Turkey related lineages are
indicated by names given from the FMD World Reference Laboratory. The vaccine lineage (since 2000) IRN 96 is subdivided
into two parts, linked to the year of collection. The first occurring isolate, within the IRN 99 cluster is indicated by an asterisk.
Formats of sequence name: accession number-country/province-year/month, year of collection. Sequences ending with a '#'
are kindly provided by IAH Pirbright.

Page 4 of 13
(page number not for citation purposes)

BMC Veterinary Research 2006, 2:35

AJ251477 O1 Manisa Turkey 1969

http://www.biomedcentral.com/1746-6148/2/35

Vaccine lineage
DQ165055 Iran 2004
DQ164896 Iran 2001
0.99
DQ165049 Iran 2003
DQ165051 Iran 2003
1.00
DQ165050 Iran 2003
0.76
DQ165056 Iran 2004
0.29
DQ164898 Iran 2003
0.56
0.74
0.40
DQ296502 Mersin/01.04
1.00
DQ296503 Mersin/02.04
0.35
DQ296501 Mersin/02.04
1.00
DQ165062 Pakistan 2002
1.00
DQ165063 Pakistan 2002
0.34
DQ165064 Pakistan 2002
DQ165065 Pakistan 2003
1.00
DQ164943 Pakistan 2003
DQ296505 Sivas/02.01
1.00
DQ296504 Igdir/08.98
DQ296516 Ankara/12.99
DQ296517 Kirsehir/06.01
0.36
DQ296500 Tokat/09.03
1.00
DQ296499 Erzincan/10.03
DQ296523 Ankara/10.02
0.64
0.75
0.21
DQ296518 Ankara/11.02
1.00
DQ296519 Sivas/03.02
DQ296520 Kirsehir/03.03
0.55 0.99
1.00
DQ296522 Erzincan/10.02
DQ296521 Malatya/04.02
DQ296531 K.Maras/08.03
1.00
DQ296530 Amasya/04.04
0.45
DQ296498 Afyon/06.04
1.00
DQ296527 Afyon/06.04
DQ296525 Afyon/04.04
1.00
DQ296526 Kutahya/05.04
DQ296528 Kutahya/05.04
AY312589 South Korea 2004
DQ296515 Konya/10.99
AF506822 Tibet 1999
AY333431 China 2000
0.88
AF377945 South Korea 2000
AJ318831 Tibet 1999
AJ294927 Taiwan 1999
AJ539137 Taiwan 1999
0.32
AJ539136 Taiwan 1999
AJ539139 South Korea 2000
0.92
1.00
AY312587 South Korea 2000
AY593824 South Korea 1985
AB079061 Japan 2000
0.93
AJ539140 South Africa
AJ539141 United Kingdom 2001
1.00
AJ633821 France 2001
1.00
AY593832 United Kingdom 2001
AY593831 United Kingdom 2001
1.00
AY593836 United Kingdom 2001
AJ539138 Tibet 1999
AJ318832 China 1999
DQ296513 Ankara/03.01
DQ296512 K.Maras/02.03
0.35
DQ372716 Israel 2005
0.28
0.99
DQ296511 Erzincan/04.03
1.00
DQ164991 Turkey 2003
DQ296510 Eskisehir/09.03
0.84
1.00
DQ296514 Denizli/11.03
0.34
DQ296509 Nigde/08.03
0.83
DQ296497 Denizili/02.03
0.90
DQ296508 Denizili/03.03
DQ296507 Denizil/03.03
1.00
DQ296506 Denizili/02.03
DQ164919 Lebanon 2003
0.99
DQ164902 Israel 2004
1.00
DQ165053 Iran 2004
DQ164901 Israel 2004
DQ164900 Israel 2004
0.52

0.99

1.00

0.1

I

A

II

I
Panasia

B

II

Figure
lished sequences (grey)
Bayesian3phylogenetic analysis of the 1D (VP1) nucleotide sequence of Turkish serotype O isolates (black) and related pubBayesian phylogenetic analysis of the 1D (VP1) nucleotide sequence of Turkish serotype O isolates (black) and
related published sequences (grey). The vaccine strain O1 Manisa is used as outgroup. Numbers on the nodes indicate
clade credibility values. Formats of sequence name: accession number-country/province-year/month, year of collection.

Page 5 of 13
(page number not for citation purposes)

BMC Veterinary Research 2006, 2:35

substitutions, with regard to the vaccine lineage, is lowest
in the group members obtained from outbreaks in Pakistan in 2002 and 2003, intermediate in the Iranian isolates from 2003 and 2004 and most advanced in the
Turkish isolates from 2004.
Group II of cluster A consists of Turkish isolates obtained
from outbreaks in the provinces Sivas in 2001 and Igdir in
1998. The latter province is close to the Iranian border.
The majority of Turkish isolates belong to cluster B, which
can also be subdivided into two groups I and II.
Cluster I of group B was further subdivided into two lineages. One group consists of isolates, obtained only from
outbreaks in Turkey and the other of isolates known as the
Panasia lineage. This partition is supported by a clade
credibility value of 0.45. The Turkish lineage displays an
increasing differential success rate, with regard to the vaccine strain O1/Manisa/69, starting from the DQ296516
Ankara/12.99 isolate, obtained in the Ankara province in
1999, towards the DQ296528 Kutahya/05.04 isolate,
obtained in the Kutahya province in 2004.
Cluster II of group B consists of viruses obtained from outbreaks in Turkey, Israel and Lebanon, with the earliest
obtained from an outbreak in the Turkish Ankara region
in 2001.
Positive selection analysis
The examination of the deduced VP1 amino acid
sequences of the serotype O isolates for selective pressures, show no significant (defined as p > 0.5) evidence
for positive selection (data not shown). On the contrary,
residue 151 of serotype A isolates displays significant evidence (p = 0.29) for positive selection (Figure 4 and additional file 1). Residue 151 is located in the immunodominant GH-loop of the VP1 molecule and therefore
particularly exposed to the immune system of the host.

By investigating the inferred ancestor history of site 151
(additional file 2 and 3), it can be seen that all but two of
the IRN96 isolates, DQ296532 and DQ296533, each collected from the same outbreak, have the common ancestor codon 'AGC' (Ser), whereas IRN99 has most likely the
'GGG' (Gly) codon as precursor.
Comparing the translated amino acid sequences of the
whole GH-loop region, located within the residues 140â€“
160 (Figure 5), reveals that IRN99 isolates consistently
deviates from IRN96 isolates by a deletion at site 153 as
well as in lineage specific conserved amino acids at the
sites: 144, 166, 183, 202 and 203. The integrin-binding
site Arg-Gly-Asp (RGD) [8], was in all serotype A isolates,
but DQ296540, as 'RGDLGAL'-motif present.

http://www.biomedcentral.com/1746-6148/2/35

Structural analysis
To compare the VP1 protein secondary structure we analysed the putative hydrophobic and hydrophilic regions
along the length of the VP1 amino acid sequence, using
the Kyte and Doolittle algorithm [10]. This revealed three
different regions for the consensus sequences of the
IRN99 and IRN96 lineages (Figure 6a), as well as two
major disparate regions for representatives of the serotype
O lineages (Figure 7a). The structural alignment of the tertiary structure, based on the consensus sequences of
IRN99 and IRN96 (Figure 6b), shown 75% sequence
identity, revealed appreciable structural differences
between the lineages, within the regions indicated by the
hydrophobicity plot. There is evidence that the IRN96 lineage has two Î²-sheet structures at the amino acid positions
40â€“55 and 105â€“124, where IRN99 has none, as well as a
different helix-structure at position 140â€“159 (Figure 6b).

From the hydrophobicity plot, DQ296505 Sivas/02.01
seems to represent the most distinct lineage of the Turkish
serotype O isolates (Figure 7a). However, the structural
alignment between DQ296505 Sivas/02.01 and the vaccine strain O1/Manisa/69, displays a high similarity of
99% (Figure 7b).

Discussion
The similarity plot (Figure 1), as well as the phylogenetic
analysis of serotype A (Figures 2), confirms the presence
of two independent lineages within our collection of isolates. A member of the IRN96 cluster was not included in
vaccines before September 2000, which means that the
vaccines before that did not provide sufficient protection
against IRN96 strains. However, the IRN96 isolates (Figure 2, IRN96 II) collected from outbreaks in 2004, and the
clustering of these isolates with the IRN96 isolates from
Iran and Iraq alternatively suggests multiple introductions
from one or both of these countries.
The IRN99 lineage is suggested to be a newly introduced
lineage rather than an escape mutant lineage evolved from
IRN96. This is supported by the lack of evolutionary intermediates between the two clusters, the consistent differences between isolates of the two clusters and the low
probability of a common ancestor of residue 151 potentially subject to positive selection. In addition that the first
IRN99 isolate reported in Turkey originate from an outbreak in the province of Igdir, close to the Iranian border.
The structural alignment of IRN99 and IRN96 (Figure 6)
revealed significant conformational differences within
this important immuno-dominant protein suggesting an
immunological advantage of IRN 99 strains given that a
member of the IRN96 is used as a vaccine component.
However, antigenic comparisons based on virus neutralisation analysis and epidemiological data previously
reported [12] do not substantiate such a conclusion.

Page 6 of 13
(page number not for citation purposes)

BMC Veterinary Research 2006, 2:35

http://www.biomedcentral.com/1746-6148/2/35




  
 

     

Sliding window representing the rate of synonymous and nonsynonymus nucleotide substitutions per site from serotype A
Figure 4
sequences
Sliding window representing the rate of synonymous and nonsynonymus nucleotide substitutions per site from
serotype A sequences. The extent of positive and negative selection on individual codons. The value above and below the
abscissa, indicates the number of per-site nonsynonymus substitutions (dN) over per-site synonymous ones (dS) in an individual
codon. The zero value means dN = dS. Site 151 shows evidence for significant positive selection (P < 0.05) based on the
extended binomial distribution.
Recalling the fact that structures are more conserved in
evolution than sequences, these observed differences support the idea of an independently evolved IRN99 lineage.
Recombination events between the two serotype A types
IRN99 and IRN96 within the 1D region were not detected
by the similarity scan. This may indicate that both serotypes A types are in the phase of high fitness and have
found their particular ecological niche.
In contrast to the serotype A strains, the serotype O isolates included in this study constitute a more homogeneous group, as shown by the similarity plot (Figure 1).
The phylogenetic analysis of serotype O isolates demonstrate the presence of two major subtypes, cluster A and B

(Figure 3), each further subdivided in distinct lineages.
Cluster A I contained isolates from one single outbreak in
the Turkish Mersin province, as well as isolates obtained
from earlier outbreaks in Pakistan and Iran. The temporal
distribution and the differential success of these isolates,
i.e. the branch lengths, suggest that the virus was introduced from Pakistan to Iran and then to Turkey. Cluster A
II, consisting of the Turkish isolates DQ296505 Sivas/
02.01 and DQ296504 Igdir/08.98, is well separated from
A I and represent a sublineage only observed in Turkey.
The same conclusion may be valid for the cluster B I,
which also exclusively comprised Turkish isolates. However, the intermediate clade credibility value of 0.45 at the
node between cluster B I and the Panasia lineage may
indicate a closer relationship to the pandemic Panasia lin-

Page 7 of 13
(page number not for citation purposes)

BMC Veterinary Research 2006, 2:35

http://www.biomedcentral.com/1746-6148/2/35

positive selected site

IRN96

IRN99

Figure 5
Amino Acid â€“ alignment of the GH-loop (residues 140â€“160) from both serotype A lineages IRN99 and IRN96
Amino Acid â€“ alignment of the GH-loop (residues 140â€“160) from both serotype A lineages IRN99 and IRN96.
Virus isolates are named after the Genbank Accession-number. Complete deletion at site 153 of the IRN99 lineage, as well as
lineage specific conserved amino acids at the sites: 144, 166, 183, 202 and 203. The potential integrin binding site Arg-Gly-Asp
(RGD) [8], is in all but DQ296541, as 'RGDLGAL'-motif present.

eage than displayed in the phylogenetic tree. An explanation for these purely Turkish sublineages may be that the
virus is circulating in Turkish cattle herds, either through
subclinically infected cattle or by transmission to cattle
from other reservoirs such as sheep and goats.
Cluster B II is clearly separated from the Panasia lineage,
consisting of isolates from newer outbreaks in Turkey,
Israel and Lebanon, indicating the spread of this sublineage.
Nevertheless, the structural comparison between the field
isolates and the vaccine strain O1/Manisa/69 (Figure 8)
displayed no distinct differences suggesting that the vaccine strain, O1/Manissa/69, in current use should provide
full protection. This suggestion is concordant with other
studies [11,12].

Conclusion
In conclusion, this study confirmed the presence of two
major serotype A lineages, namely IRN 99 and IRN96, in
Turkey. There was no evidence that the A22 strain was
present in Turkey during the examined period of time,
however this may be related to the small sample size used
in this study. The sequence and structural analysis of the
IRN99 related viruses revealed potential conformational
differences of the IRN99 VP1 possibly affecting the antigenic properties of particular regions. There is evidence

that IRN99 is introduced from outside to Turkey, in all
probability from Iran.
Since, the IRN96 lineage is a component of the FMDV vaccine used since 2000, the outbreaks in 2004 occurred
most probably due to incomplete vaccine coverage.
The endemic, slowly evolving Turkish O lineages, with a
predicted VP1 structure similar to the O1 Manisa vaccine,
occurs in several sublineages in Turkey. Some of these
sublineages are most probably introduced from neighbouring countries, whereas others are circulating within
Turkish cattle or are frequently reintroduced to cattle from
persistently infected small ruminants, i.e. sheep and goats,
which share pastures and transport vehicles.

Methods
Virus isolates
Thirty-three serotype O (Accession numbers: DQ296497
â€“ DQ296531) and twenty serotype A (Accession numbers:
DQ296532 â€“ DQ296552) field isolates were collected
from 1998 to 2004 from bovine herds widely distributed
in Turkey. All isolates were epidermal tissue samples representing vesicular lesions and had been stored in TRIZOLÂ©-reagent. Province and time (month/year) of
collection are indicated with the accession numbers.

Page 8 of 13
(page number not for citation purposes)

BMC Veterinary Research 2006, 2:35

http://www.biomedcentral.com/1746-6148/2/35

a
3

IRN99
IRN96

Kyte & Doolittle hydrophobicity scores

2

1

0

-1

-2

-3

-4
3

13

23

33

43

53

63

73

83

93

103
1
113
13
position

123

133

143

153

163

173

183

193

b
IRN99
IRN96

Amino Acid Hydrophobicity plot (a) and structural alignment (b) based on the consensus sequences of the both serotype A linFigure 6
eages IRN99 andIRN96
Amino Acid Hydrophobicity plot (a) and structural alignment (b) based on the consensus sequences of the
both serotype A lineages IRN99 andIRN96. Significant differences are indicated by coloured bar, where the colour refers
to the part of the structural model.

Page 9 of 13
(page number not for citation purposes)

BMC Veterinary Research 2006, 2:35

http://www.biomedcentral.com/1746-6148/2/35

a
DQ296502 Mersin/01.04
DQ296518 Ankara/11.02
DQ296509 Nigde/08.03
DQ296504 Igdir/08.98
DQ296505 Sivas/02.01
O1 Manisa

4

Kyte & Doolittle hydrophobicity scores

3

2

1

0

-1

-2

-3

-4
3

b

13

23

33

43

53

63

73

83

93

103
113
position

123

133

143

153

163

173

183

193

203

AJ251477 O1 Manisa
DQ296505 Sivas/02.01

Figure 7
subtypes
Amino Acid Hydrophobicity plot (a) and structural alignment (b) based on the consensus sequences of the main serotype O
Amino Acid Hydrophobicity plot (a) and structural alignment (b) based on the consensus sequences of the
main serotype O subtypes. Significant differences are indicated by coloured bar, where the colour refers to the part of the
structural model.

Page 10 of 13
(page number not for citation purposes)

BMC Veterinary Research 2006, 2:35

http://www.biomedcentral.com/1746-6148/2/35

RNA extraction, reverse transcriptase â€“ PCR and cycle
sequencing
Tissue (100â€“150 mg) was homogenized in 1 ml RNAproâ„¢
Solution (Qbiogene, USA) in a Lysing Matrix D tube
(Qbiogene, Inc., USA) using a FP 120 Fast Prepâ„¢ Cell Disruptor (Qbiogene, USA). Total RNA was extracted using
RNeasy-Mini Kitâ„¢ (Qiagen, Germany) according to manufacturer's instructions. cDNA synthesis was done using

Ready-To-Goâ„¢ You-Prime First-Strand Beads (GE Healthcare Life Sciences, Sweden), employing the primers
NV27T and random hexamers pdN6.
Five Î¼l of the template cDNA were added to 45 Î¼l of the
PCR reaction mixture containing 0,2 Î¼M primers (see
Table 1), 200 Î¼M each of dATP, dCTP, dGTP and dTTP, 10
mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2 and 1
U of AmpliTaqÂ® Gold DNA polymerase (Applied Biosystems, UK). DNA was amplified with a DNA Thermal
Cycler PE9700 (Perkin Elmer) by a two-step cycling reaction as follows: 95Â°C for 15 min, and five cycles of 94Â°C
for 30 sec, 57Â°C for 2 min and 72Â°C for 30 sec, and then
35 cycles of 94Â°C for 30 sec, 61Â°C for 30 sec and 72Â°C for
30 sec, followed by a final extension step of 72Â°C for 10
min.
The resulting PCR product was examined by electrophoresis, using a 1,2% agarose gel, containing 0,005% ethidium
bromide, with a separation time of 1,5 hours at 6,5 V/cm.
Amplicons were extracted and purified from agarosegel
with QIAquick Gel Extraction kit (Qiagen, Germany) and
cycle-sequencing was then performed by Agowa GmbH,
Germany.
Multiple alignment
Sequence assembling was performed with ContigExpress
(VectorNTIÂ©-software) and multiple alignment was performed by log-expectation comparison, using the MUS-

CLE (v.3.6) software [13]. For the serotype A alignment
manual editing at codon position 153 was done.
Similarity analysis
Similarity plots were performed using Simplot software
[14] with the following parameters: For serotype A a windows size of 100 bp (step: 20 bp) with gap-stripping and
Jukes-cantor correction was chosen, whereas a window of
200 bp (step:20 bp) with gap-stripping and Kimura (2parameter) correction was chosen for serotype O.
Phylogenetic analysis
Models of evolution were determined by hierarchical
Likelihood-Ratio test of 24 substitution models, using the
programs PAUP*(v. 10) [15] and MrModeltest (v. 2.2)
[16].

For serotype A the HKY+G was used and Bayesian analysis
was performed using MrBayes (v3.2) [17] with the following settings. The maximum likelihood model employed 2
substitution types ("nst = 2"), with base frequencies set to
fixed values ("statefreqpr = fixed"). Rate variation across
sites was modelled using a gamma distribution (rates =
"gamma"). The Markov chain Monte Carlo search was run
with 4 chains for 500000 generations, with trees begin
sampled every 100 generations (the first 1000 trees were
discarded as "burnin").
For serotype O the GTR+G was used and Bayesian analysis
was performed using MrBayes (v3.2) [17] with the following settings. The maximum likelihood model employed 6
substitution types ("nst = 6"), with base frequencies set to
variable values ("statefreqpr = dirichlet(1,1,1,1)"). Rate
variation across sites was modelled using a gamma distribution (rates = "invgamma"). The Markov chain Monte
Carlo search was run with 4 chains for 500000 generations, with trees begin sampled every 100 generations (the
first 1000 trees were discarded as "burnin").

Table 1: Primers used in this study

Sense/Antisense

Designation

Sequence (5' to 3')

Sense
Sense
Sense
Antisense
Sense
Antisense
Sense
Antisense
Sense
Antisense
Sense
Antisense

O-1C244F
O-1C272F
O-1C283F
NK61
SV1
P1
P498Â¶
P617 rc
A1
A2
B1
B2

GCAGCAAAACACATGTCAAACACCTT
TBGCRGGNCTYGCCCAGTACTAC
GCCCAGTACTACACACAGTACAG
GACATGTCCTCCTGCATCTG
GCGCCACACCGCGTGTTGG
GAAGGGCCCAGGGTTGGACTC
AATTACACATGGCAAGGCCGACGG
CCCGAGTGGCTTTGATGG
ACCAATGTACAGGGATGGGT
TTGCACCGTAGTTAAAGGAA
CTGAGAGAGCTGCACACTGC
GTACTTGCTCGTCCCGTTGT

Published by
[26]
[26]
[26]
[26]
[27]
[27]
[28]
[28]
This study
This study
This study
This study

Page 11 of 13
(page number not for citation purposes)

BMC Veterinary Research 2006, 2:35

http://www.biomedcentral.com/1746-6148/2/35

Selection pressure analysis
Positively selected sites (Codon-specific analyses of dN/
dS) was identified using the Single Likelihood Ancestor
Counting (SLAC) analysis [18], a modification of the
Suzuki-Gojobori method [19], available at the Datamonkey web side [18]. For both serotypes, the analysis was
done with the HKY85 substitution model on phylogenetic
trees inferred using the Neighbour-Joining method with a
cut-off p value of 0.5.
Structural analysis
Three-dimensional structure of the VP1 protein was
obtained using comparative protein modelling [20],
employing the CPHmodels 2.0 Server [21] and pairwise
structure comparison was done using the DaliLite workbench [22]. Molecule Visualization was done using RASMOL 2.7 software [23].

The structural analysis of the A serotype is based on the
comparison of the translated amino acid consensus
sequences from the IRN96 and IRN99 lineage. Both,
IRN99 consensus and IRN96 consensus sequences, used
the structure of serotype A-1061 (1ZBA:1; Resolution: 2 Ã…)
[24] as template.

Additional file 3
Ancestral State Reconstruction of the amino acid of site 151 mapped
to a phylogeny. Using the Maximum Likelihood the codons ancestral
sequence is determined. The arrow indicates the changeover between the
both lineages IRN99 and IRN96.
Click here for file
[http://www.biomedcentral.com/content/supplementary/17466148-2-35-S3.pdf]

Acknowledgements
We thank Gert Olsen and Anita Bagge Hemmingsen for excellent technical
assistance, SÃ¸ren Alexandersen, Jens Nielsen and Thomas Bruun Rasmussen for useful discussions and Nick Knowles for supplying sequence information.
This work was funded by the FMD improcon project of the European
Union Improvement of Foot and Mouth disease control by ethically acceptable methods based on scientifically validated assays and new knowledge on
FMD vaccines, including the impact of vaccination (grant no. SSPE-CT-2003503603).

References
1.
2.

For serotype O viruses the structural analysis was based on
the translated amino acid sequences of DQ296505 Sivas/
02.01 and the vaccine strain O1/Manisa/69. Both used the
structure of strain O-1860 (1FOD:1; Resolution: 2,6 Ã…)
[25] as template.

Authors' contributions
JK carried out the molecular epidemiological studies, the
sequence and structure analysis and drafted the manuscript. ÃœP and FÃ– collected the field isolates. LSC conceived the study, and participated in its design and
coordination and helped to draft the manuscript. All
authors read and approved the final manuscript.

3.

4.
5.
6.
7.

Additional material
8.

Additional file 1
SLAC and REL results
Click here for file
[http://www.biomedcentral.com/content/supplementary/17466148-2-35-S1.pdf]

9.

Additional file 2

11.

Ancestral State Reconstruction of the codon sequence of site 151
mapped to a phylogeny. Using the Maximum Likelihood the codons
ancestral sequence is determined. The arrow indicates the changeover
between the both lineages IRN99 and IRN96.
Click here for file
[http://www.biomedcentral.com/content/supplementary/17466148-2-35-S2.pdf]

10.

12.

13.
14.

Rohrer H, Olechnowitz AF: Maul-und Klauenseuche Jena, Germany:
VEB Gustav Fischer Verlag; 1980.
Domingo E, Pariente N, Airaksinen A, Gonzalez-Lopez C, Sierra S,
Herrera M, Grande-Perez A, Lowenstein PR, Manrubia SC, Lazaro E,
Escarmis C: Foot-and-mouth disease virus evolution: exploring pathways towards virus extinction. Curr Top Microbiol Immunol 2005, 288:149-173.
Askaroglu H: Report on the FMD situation and control programme in Turkey. In European commission for the control of Footand-Mouth Disease Report of the Sixty-eighth Session of the Executive
Committee Vilnius, Lithuania 7 and 8 November 2002 FAO Rome; 2002.
EUFMD-REPORTS 63rd Session â€“ Appendix 3
[http://
www.fao.org/AG/AGAInfo/commissions/en/eufmd/app/63/
app03.html]
Kitching R: Global epidemiology and prospects for control of
foot-and-mouth disease. Curr Top Microbiol Immunol 2005,
288:133-148.
FMD Global Update 2003â€“2004 [http://www.iah.bbsrc.ac.uvirus/
Picornaviridae/Aphthovirus/WRLFMD/EUFMD-Crete/Val
archer.ppt]
Gilbert M, Aktas S, Mohammed H, Roeder P, Sumption K, Tufan M,
Slingenbergh J: Patterns of spread and persistence of foot-andmouth disease types A, O and Asia-1 in Turkey: a meta-population approach. Epidemiol Infect 2005, 133:537-545.
Fox G, Parry NR, Barnett PV, McGinn B, Rowlands DJ, Brown F: The
cell attachment site on foot-and-mouth disease virus
includes the amino acid sequence RGD (arginine-glycineaspartic acid). J Gen Virol 1989, 70:625-637.
Hernandez J, Valero ML, Andreu D, Domingo E, Mateu MG: Antibody and host cell recognition of foot-and-mouth disease
virus (serotype C) cleaved at the Arg-Gly-Asp (RGD) motif:
a structural interpretation. J Gen Virol 1996, 77:257-264.
Kyte J, Doolittle RF: A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982, 157:105-132.
Aktas S: Molecular epidemiology of foot and mouth disease types O and A
in Turkey Reading University Library; 1998.
Parlak Ãœ, Ã–zyÃ¶rÃ¼k F, Knowles N, Armstrong R, Aktas S, Feray A,
Cokcaliskan C, Christensen L: Characterisation of foot-andmouth disease virus strains circulating in Turkey during
1996â€“2004. Submitted to Archives of Virology .
Edgar RC: MUSCLE: multiple sequence alignment with high
accuracy and high throughput.
Nucleic Acids Res 2004,
32:1792-1797.
Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak
NG, Ingersoll R, Sheppard HW, Ray SC: Full-length human immu-

Page 12 of 13
(page number not for citation purposes)

BMC Veterinary Research 2006, 2:35

15.
16.
17.
18.
19.
20.
21.
22.
23.
24.

25.

26.

27.

28.

http://www.biomedcentral.com/1746-6148/2/35

nodeficiency virus type 1 genomes from subtype C-infected
seroconverters in India, with evidence of intersubtype
recombination. J Virol 1999, 73:152-160.
Swofford D: PAUP*: Phylogenetic Analysis Using Parsimony (*And Other
Methods), version b4 Sinauer Associates, Sunderland, MA; 1998.
Nylander J: MrModeltest v2. Program distributed by the author Evolutionary Biology Centre, Uppsala University, Sweden; 2004.
Huelsenbeck J, Ronquist F: MRBAYES: Bayesian inference of
phylogeny. Bioinformatics 2001, 17:754-755.
Pond SL, Frost SD: Datamonkey: rapid detection of selective
pressure on individual sites of codon alignments. Bioinformatics
2005, 21:2531-2533.
Suzuki Y, Gojobori T: A method for detecting positive selection
at single amino acid sites. Mol Biol Evol 1999, 16:1315-1328.
Marti-Renom MA, Madhusudhan MS, Fiser A, Rost B, Sali A: Reliability of assessment of protein structure prediction methods.
Structure 2002, 10:435-440.
Lund O, Nielsen M, Lundegaard C, Worning P: CPHmodels 2.0:
X3M a Computer Program to Extract 3D Models. Abstract at
the CASP5 conference A102 2002.
Holm L, Park J: DaliLite workbench for protein structure comparison. Bioinformatics 2000, 16:566-567.
Roger A, Sayle E, James Milner-White E: RASMOL: biomolecular
graphics for all. Trends Biochem Sci 1995, 20:374.
Fry E, Newman J, Curry S, Najjam S, Jackson T, Blakemore W, Lea S,
Miller L, Burman A, King A, Stuart D: Structure of Foot-andmouth disease virus serotype A1061 alone and complexed
with oligosaccharide receptor: receptor conservation in the
face of antigenic variation. J Gen Virol 2005, 86:1909-1920.
Logan D, Abu-Ghazaleh R, Blakemore W, Curry S, Jackson T, King A,
Lea S, Lewis R, Newman J, Parry N, Rowlands D, Stuart D, Fry E:
Structure of a major immunogenic site on foot-and-mouth
disease virus. Nature 1993, 362:566-568.
Knowles NJ, Davies PR, Midgley RJ, Valarcher JF: Identification of a
Ninth Foot-and-Mouth Disease Virus Type O Topotype and
Evidence for a Recombination Event in its Evolution. 1993
[http://www.fao.org/AG/AGAInfo/commissions/docs/greece04/
App24.pdf]. Available online (10.05.2006):
Locher F, Suryanarayana VV, Tratschin JD: Rapid detection and
characterization of foot-and-mouth disease virus by restriction enzyme and nucleotide sequence analysis of PCR products. J Clin Microbiol 1995, 33:440-444.
Mason PW, Pacheco JM, Zhao QZ, Knowles NJ: Comparisons of
the complete genomes of Asian, African and European isolates of a recent foot-and-mouth disease virus type O pandemic strain (PanAsia). J Gen Virol 2003, 84:1583-1593.

Publish with Bio Med Central and every
scientist can read your work free of charge
"BioMed Central will be the most significant development for
disseminating the results of biomedical researc h in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central
yours â€” you keep the copyright

BioMedcentral

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

Page 13 of 13
(page number not for citation purposes)

</pre>
</body>
</html>
